Antibodies (Nov 2023)

The Role of Antibody-Based Therapies in Neuro-Oncology

  • Rishab Ramapriyan,
  • Jing Sun,
  • Annabel Curry,
  • Leland G. Richardson,
  • Tarun Ramesh,
  • Matthew A. Gaffey,
  • Patrick C. Gedeon,
  • Elizabeth R. Gerstner,
  • William T. Curry,
  • Bryan D. Choi

DOI
https://doi.org/10.3390/antib12040074
Journal volume & issue
Vol. 12, no. 4
p. 74

Abstract

Read online

This review explores the evolving landscape of antibody-based therapies in neuro-oncology, in particular, immune checkpoint inhibitors and immunomodulatory antibodies. We discuss their mechanisms of action, blood-brain barrier (BBB) penetration, and experience in neuro-oncological conditions. Evidence from recent trials indicates that while these therapies can modulate the tumor immune microenvironment, their clinical benefits remain uncertain, largely due to challenges with BBB penetration and tumor-derived immunosuppression. This review also examines emerging targets such as TIGIT and LAG3, the potential of antibodies in modulating the myeloid compartment, and tumor-specific targets for monoclonal antibody therapy. We further delve into advanced strategies such as antibody–drug conjugates and bispecific T cell engagers. Lastly, we explore innovative techniques being investigated to enhance antibody delivery, including CAR T cell therapy. Despite current limitations, these therapies hold significant therapeutic potential for neuro-oncology. Future research should focus on optimizing antibody delivery to the CNS, identifying novel biological targets, and discovering combination therapies to address the hostile tumor microenvironment.

Keywords